O
CLDX icon

OppenheimerFunds’s Celldex Therapeutics CLDX Stock Holding History

OppenheimerFunds’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-610,841
Closed -$40.2M – 1729
2016
Q2 		$40.2M Buy
610,841
+18,604
+3% +$1.18M 0.05% 371
2016
Q1 		$33.6M Sell
592,237
-1,209
-0.2% -$136K 0.04% 410
2015
Q4 		$140M Sell
593,446
-18,326
-3% -$4M 0.18% 138
2015
Q3 		$96.7M Buy
611,772
+25,450
+4% +$7.2M 0.13% 190
2015
Q2 		$222M Sell
586,322
-22,022
-4% -$8.75M 0.25% 110
2015
Q1 		$254M Sell
608,344
-11,861
-2% -$4.24M 0.28% 100
2014
Q4 		$170M Buy
620,205
+31,993
+5% +$7.95M 0.19% 144
2014
Q3 		$114M Buy
588,212
+1,775
+0.3% +$387K 0.13% 193
2014
Q2 		$144M Buy
586,437
+200,740
+52% +$45.3M 0.16% 166
2014
Q1 		$102M Buy
385,697
+134,982
+54% +$51.7M 0.12% 203
2013
Q4 		$91M Buy
250,715
+234,121
+1,411% +$90.2M 0.11% 216
2013
Q3 		$8.82M Buy
+16,594
New +$5.69M 0.01% 726

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OppenheimerFunds's CLDX Position: Q3 2016 in Review

OppenheimerFunds sold out of Celldex Therapeutics (CLDX) in Q3 2016, closing a stake of 610,841 shares — an estimated $40.2M sold.

OppenheimerFunds first reported a position in CLDX in Q3 2013 and held it in 12 quarters. The position peaked at $254M in Q1 2015. 138 funds tracked by Wall St. Rank hold CLDX as of Q3 2016.

  • OppenheimerFunds reported no remaining Celldex Therapeutics position as of Q3 2016 after selling out during the quarter.
  • OppenheimerFunds sold 610,841 Celldex Therapeutics shares in Q3 2016, an estimated $40.2M.
  • OppenheimerFunds first reported a position in Celldex Therapeutics in Q3 2013 and held it in 12 quarters.
  • OppenheimerFunds's Celldex Therapeutics position peaked at $254M in Q1 2015.
  • 138 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2016.

Based on OppenheimerFunds's 13F filing for Q3 2016, filed 14 Nov 2016.